AstraZeneca spinout Entasis gets $50 mln to fight drug-resistant bacteria
Entasis Therapeutics, an AstraZeneca spinout developing products to treat drug-resistant bacterial infections, announced it has completed a $50 million Series B financing led by Clarus. Other investors included AstraZeneca, Frazier Healthcare Partners, Eventide Funds and Novo A/S. Entasis, based in Waltham, Massacusetts, raised a $40 million Series A from AstraZeneca in March 2015.
4 April 2016•5 mins read
